Fairvalue-Calculator Fairvalue-Calculator
EN DE

ArcticZymes Technologies ASA (AZT) Fair Value & Analysis

Healthcare · NO · Market cap 1.1B NOK

Pricekr 20.30
Fair Valuekr 4.26
Upside-79.0%
Quality95/100
Evidence: High Range kr 4.05 – kr 5.32

Fair value as of: Jun 24, 2026

Analysis

ArcticZymes Technologies ASA (AZT) currently trades at kr 20.30, while our model-based Fair Value estimate is kr 4.26 — implying the stock looks roughly 79.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase; cod UNG for use in viral and other molecular diagnostic assays for the removal of contaminating dU-DNA; salt active nucleases for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; and double-strand specific DNases and derived kits for the removal of double stranded DNA. It also provides DNA/RNA polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining nucleic acids. The company serves the molecular tools market, and biomanufacturing markets. It operates in Norway, Germany, Lithuania, France, Italy, the United Kingdom, rest of Europe, the United States,…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is ArcticZymes Technologies ASA (AZT) undervalued?
As of Jun 24, 2026, our model estimates a fair value of kr 4.26 versus a price of kr 20.30 — about −79% (overvalued). Model-based estimate, not financial advice.
What is the fair value of AZT?
Our 21-model fair value for ArcticZymes Technologies ASA is kr 4.26 (as of Jun 24, 2026), built from audited fundamentals. The current price is kr 20.30.
What is the quality score of AZT?
ArcticZymes Technologies ASA has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.